Results 51 to 60 of about 3,528 (147)
The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults
Frontiers in Microbiology, 2022 Vaccination is one of the best ways to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic. Among the various SARS-CoV-2 vaccines approved for use, the BBIBP-CorV inactivated vaccine has been widely used in 93 countries.Qinjin Wang, Jie Ning, Ying Chen, Bin Li, Liang Shi, Taojun He, Fang Zhang, Xingchi Chen, Aixia Zhai, Chao Wu +9 moredoaj +1 more sourceImmunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique. [PDF]
Clin Infect DisBACKGROUND: Data on immunogenicity and safety of heterologous prime-boost (HePB) regimens using the BBIBP-CorV and Ad26.COV2.S have not yet been reported in sub-Saharan Africa.Ramgi P, Siribie M, Rakotozandrindrainy N, Bule O, Shrivastava H, Chambule L, Park EL, Fernando C, Boque J, Macuiana R, Razafimanantsoa R, Rakotozandrindrainy N, Razafindrabe TJL, Rakotoarisoa AN, Raminosoa TM, Derandrainy HL, Rakotoson MM, de Silva CSS, Mutombene M, Massinga C, Langa JP, Guarnacci T, Kang SSY, Jo SK, Jeon HJ, Excler JL, Yang Y, Wang S, Sugimoto JD, Yang JS, Shim BS, Binger T, Capitine IU, Aziz AB, Park JY, Kim DR, Rakotozandrindrainy R, Jani IV, Tadesse BT, Marks F. +39 moreeuropepmc +2 more sourcesSafety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial
Signal Transduction and Targeted Therapy, 2023 An ongoing randomized, double-blind, controlled phase 2 trial was conducted to evaluate the safety and immunogenicity of a mosaic-type recombinant vaccine candidate, named NVSI-06-09, as a booster dose in subjects aged 18 years and older from the United ...Nawal Al Kaabi, Yun Kai Yang, Yu Liang, Ke Xu, Xue Feng Zhang, Yun Kang, Yu Qin Jin, Jun Wei Hou, Jing Zhang, Tian Yang, Salah Hussein, Mohamed Saif ElDein, Ze Hua Lei, Hao Zhang, Shuai Shao, Zhao Ming Liu, Ning Liu, Xiang Zheng, Ji Guo Su, Sen Sen Yang, Xiangfeng Cong, Yao Tan, Wenwen Lei, Xue Jun Gao, Zhiwei Jiang, Hui Wang, Meng Li, Hanadi Mekki Mekki, Walid Zaher, Sally Mahmoud, Xue Zhang, Chang Qu, Dan Ying Liu, Jing Zhang, Mengjie Yang, Islam Eltantawy, Peng Xiao, Fu Jie Shen, Jin Juan Wu, Zi Bo Han, Li Fang Du, Fang Tang, Shi Chen, Zhi Jing Ma, Fan Zheng, Ya Nan Hou, Xin Yu Li, Xin Li, Zhao Nian Wang, Jin Liang Yin, Xiao Yan Mao, Jin Zhang, Liang Qu, Yun Tao Zhang, Xiao Ming Yang, Guizhen Wu, Qi Ming Li +56 moredoaj +1 more sourceThe incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates
Scientific Reports, 2022 Based on the findings from the Phase III clinical trials of inactivated SARS COV-2 Vaccine, (BBIBP-CORV) emergency use authorization (EUA) was granted for the vaccine to frontline workers in the UAE.Nawal Al Kaabi, Abderrahim Oulhaj, Farida Ismail Al Hosani, Shamma Al Mazrouei, Omer Najim, Salah Eldin Hussein, Jehad Saleh Abdalla, Mohammed Saifuddin Fasihuddin, Afnan Abdellatif Hassan, Gehad Elghazali, Ahmed Al Rumaithi, Jumana Al Azazi, Stefan Weber, Rami Beiram, Khatija A. Parekh, Mohamud Sheek-Hussein, Yunkai Yang, Yang Xiaoming, Jenny Quliang, Islam Eltantawy, Sally Mahmoud, Ashish Koshy, Peng Xiao, Subhashini Ganesan, Wael Elamin, Walid Zaher +25 moredoaj +1 more sourceSafety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trialResearch in context
EClinicalMedicine, 2023 Summary: Background: COVID-19 vaccines that offer broad-spectrum protection are needed. We aimed to evaluate the safety and immunogenicity of multivalent vaccines, SCTV01E and SCTV01C, and compare them with an inactivated vaccine.Suad Hannawi, Lixin Yan, Linda Saifeldin, Alaa Abuquta, Ahmad Alamadi, Sally A. Mahmoud, Aala Hassan, Miaomiao Zhang, Cuige Gao, Yuanxin Chen, Wenlin Gai, Liangzhi Xie +11 moredoaj +1 more sourceDemographic and clinical characteristics of volunteers in the homologous and heterologous ChAdOx1-S and BBIBP-CorV vaccine groups.
, 2023 Demographic and clinical characteristics of volunteers in the homologous and heterologous ChAdOx1-S and BBIBP-CorV vaccine groups.Carmen Valenzuela Silva (17319206), Amitis Ramezani (6329339), Alireza Biglari (12152590), Sana Eybpoosh (2826068), Anahita Bavand (6329345), Mostafa Salehi-Vaziri (6273803), Mohammad Banifazl (17319212), Sarah Dahmardeh (17319209), Vicente Verez-Bencomo (17319200), Rahim Sorouri (17319194), Maria Eugenia Toledo-Romani (17319203), Ehsan Mostafavi (406077), Mona Sadat Larijani (17319197), Delaram Doroud (348344), Fatemeh Ashrafian (9619876) +14 morecore +1 more sourceSafety and immunogenicity of heterologous COVID-19 vaccine regimens to deal with product shortage: A randomised clinical trial in an elderly population
Public Health in Practice, 2022 Objectives: In a context of COVID-19 vaccine shortages, this study sought to evaluate the safety and efficacy of receiving one dose of Gam-COVID-Vac rAd26 followed by a second COVID-19 vaccine dose of either Gam-COVID-Vac rAd5, ChAdOx1 nCoV-19 or BBIBP ...M.A. Kundro, M.H. Losso, A. Macchia, I. Pastor, M. Alonso Serena, C. Gestoso, L. Moreno Macías, F. Crupi, M.C. Acosta, S. Ivalo, M. Ghioldi, M.B. Bouzas, L. Mammana, I. Zapiola, I. Mazzitelli, A. Varese, J. Geffner, C. Biscayart, P. Angeleri, E. Lopez, A. Gentile, D. Ferrante, F. Gonzalez B. de Quiros +22 moredoaj +1 more sourceAdverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
, 2022 BackgroundAdverse events following immunization (AEFI) against SARS-CoV-2 are common as reported by clinical trials and contemporary evidence. The objective of the present study was to evaluate the local and systemic adverse events following vaccination ...Sushil Rayamajhi, Dongol, Anjana Singh, Rafi, Md Abdur, Md. Abdur Rafi, Md. Golam Hossain, Bhandari, Subhechchha, Nishant Tripathi, Anjana Singh Dongol, Pranay Shrestha, Shreejana Rayamajhi, Subhechchha Bhandari, Pandey, Minalma, Hasan, M Tasdik, Rayamajhi, Sushil, Tripathi, Nishant, Hossain, Md. Golam, Shrestha, Pranay, Hossain, Md Golam, Rafi, Md. Abdur, Rayamajhi, Shreejana, Minalma Pandey, M. Tasdik Hasan, Hasan, M. Tasdik +22 morecore +1 more source
